Sveriges Riksbank
4.2.2021 13:31:27 CET | Globenewswire | Press release
| Bid date, 2021-02-04 | |
| Bid Date | 2021-02-04 |
| Bid times | 14.00-14.30 (CET/CEST) on the Bid date |
| Offerent Amount | USD 10 billion |
| Maximum Permitted Volume of Bids | USD 4 billion from an individual institution |
| Settlement Date | 2021-02-08 |
| Minimum Permitted Bid Volume | 100 USD million per bid |
| Maximum Allocation | 40 per cent of the Offerend amount |
| Allocation time | Not later than 15.00 (CET/CEST) on the Bid date |
| Maturity Date | 2021-05-03 |
| Maximum Number of Bids | 10 per individual institution |
| Lowest Bid Rate | 0.32 % |
| Confirmation of bids to e-mail | eol@riksbank.se |
Stockholm, 2021-02-02
This is a translation of the special terms and conditions published on www.riksbank.se. In the case of any inconsistency between the English translation and the Swedish language version, the Swedish language version shall prevail. Complete terms and conditions can be retrieved at www.riksbank.se.
To view this piece of content from www.globenewswire.com, please give your consent at the top of this page.To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.
About Globenewswire
Subscribe to releases from Globenewswire
Subscribe to all the latest releases from Globenewswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Globenewswire
Alkane Resources Limited30.3.2026 00:16:17 CEST | Press release
Alkane Executes $110 Million Revolving Credit Facility
Fast Ejendom Danmark29.3.2026 18:17:55 CEST | Pressemeddelelse
Aktietilbagekøbsprogram
Newcap Holdings29.3.2026 12:19:20 CEST | Pressemeddelelse
NewCap Holding A/S har indgået en aftale, betinget af underskrivelse af endelige aftaledokumenter m.v., om erhvervelse af dansk selskab indenfor compliance og risikostyringsservices – Intern viden
Novartis Pharma AG29.3.2026 07:15:00 CEST | Press release
Novartis IgAN data in New England Journal of Medicine show Fabhalta® slowed kidney function decline by 49.3%
Biogen Inc.28.3.2026 20:00:00 CET | Press release
Biogen Announces Second Positive Phase 2 Litifilimab Trial in Cutaneous Lupus Erythematosus at 2026 American Academy of Dermatology Annual Meeting, Showing a Significant Reduction in Skin Disease Activity
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
